728-90-5

Basic information

• Product Name: 2'-NITROBENZANILIDE
• Synonyms: AURORA KA-6294;2'-NITROBENZANILIDE;2-Nitro-N-benzoylaniline;Benzanilide, 2'-nitro-;N-(2-Nitrophenyl)benzamide;N-(o-Nitrophenyl)benzamide;o'-Nitrobenzanilide
• CAS NO: 728-90-5
• Molecular Formula: C₁₃H₁₀N₂O₃
• Molecular Weight: 242.23
• EINECS: 211-978-5
• Mol File: 728-90-5.mol
• Article Data: 61

Chemical Properties

• Melting Point: 155-157°C
• Boiling Point: 316.6 °C at 760 mmHg
• Flash Point: 145.3 °C
• Appearance: /
• Density: 1.344g/cm³
• PKA: 12.23±0.70(Predicted)
• CAS DataBase Reference: 2'-NITROBENZANILIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-NITROBENZANILIDE(728-90-5)
• EPA Substance Registry System: 2'-NITROBENZANILIDE(728-90-5)

Safety Data

• Hazardous Substances Data: 728-90-5(Hazardous Substances Data)

Usage

General Description

2'-Nitrobenzanilide is a chemical compound with the molecular formula C13H10N2O3. It is a yellow solid with a molecular weight of 238.23 g/mol. The compound is used as a building block in the synthesis of various organic compounds and pharmaceuticals. It is also employed in the production of dyes and pigments. Additionally, 2'-nitrobenzanilide has been studied for its potential biological activities, including its antimicrobial and anti-inflammatory properties. It is important to handle this compound with care as it may be harmful if swallowed or inhaled, and may cause skin and eye irritation upon contact.

Upstream product

• 98-88-4 benzoyl chloride 
• 88-74-4 2-nitro-aniline 
• 3320-86-3 2-nitrophenyl isocyanate 
• 23665-09-0 phenylzinc iodide 
• 591-50-4 iodobenzene 
• 93-98-1 N-phenyl benzoyl amide 
• 1493-27-2 ortho-nitrofluorobenzene 
• 100-47-0 benzonitrile 
• 29110-75-6 N'-tosyl phenylhydrazine 
• 6596-69-6 N’-phenyl benzenesulfonyl hydrazide 
• 114-83-0 1-acetyl-2-phenylhydrazine 
• 100-63-0 phenylhydrazine 
• 59-88-1 phenylhydrazine hydrochloride 
• 62-53-3 aniline 

Downstream Products

• 70326-65-7 O-Benzoylamino-phenylhydroxylamin 
• 70326-66-8 2',2''-azoxybenzanilide 
• 52010-24-9 N-(2-nitro-4-chlorophenyl)benzamide 
• 4231-62-3 1-benzoyl-1H-benzotriazole 
• 91692-55-6 benzoic acid-(4-bromo-2,6-dinitro-anilide) 
• 1571-85-3 2-phenyl-5-nitrobenzimidazole 
• 1741-50-0 5-bromo-2-phenyl-1H-benzo[d]imidazole 
• 72602-72-3 3-(2-nitrophenyl)-4-phenyl-1,2,3,5-oxathiadiazole 2-oxide 
• 72602-69-8 2-nitrophenyl(phenyl)carbodi-imide 
• 72602-71-2 4-(2-nitrophenyl)-3-phenyl-1,2,4-oxadiazole-5-thione 
• 99137-33-4 2-phenyl-1,2,4-benzotriazin-3-one 1-oxide 
• 99137-35-6 2-azoxyphenyl(4-methoxyphenyl)urea 
• 72602-70-1 4-(2-nitrophenyl)-3-phenyl-1,2,4-oxadiazol-5-one 
• 99137-19-6 N-(2-nitrophenyl)benzamidrazone 

Relevant articles and documents

Copper-mediated regioselective efficient direct ortho-nitration of anilide derivatives

The mild and readily available Cu(NO3)2 mediated ortho nitration of anilides with broad substrate using K2S2O8 as an oxidant in the absence of any other metal catalyst and nitrating agent under mild conditions was reported for the first time.

Rhodium-Catalyzed Addition of Organozinc Iodides to Carbon-11 Isocyanates

Amides were prepared using rhodium-catalyzed coupling of organozinc iodides and carbon-11 (11C, t1/2 = 20.4 min) isocyanates. Nonradioactive isocyanates and sp3 or sp2 organozinc iodides generated amides in yields of 13%-87%. Incorporation of cyclotron-produced [11C]CO2 into 11C-amide products proceeded in yields of 5%-99%. The synthetic utility of the methodology was demonstrated through the isolation of [11C]N-(4-fluorophenyl)-4-methoxybenzamide ([11C]6g) with a molar activity of 267 GBq μmol-1 and 12% radiochemical yield in 21 min from the beginning of synthesis.

A kind of sphingomyelin synthase inhibitor, its preparation method and application thereof

The invention provides general formula (I) compound of formula, its pharmaceutically acceptable salts or stereoisomers, wherein X, Y, M, Z, R and Ar respectively as defined in the specification. The invention also provides a composition comprising a therapeutically effective amount of at least one of the foregoing general formula (I) compounds of formula, its pharmaceutically acceptable salts or stereoisomers, and the above-mentioned compound, its pharmaceutically acceptable salts or stereoisomers, or the above-mentioned pharmaceutical composition in preparation for the prevention and/or treatment of sphingomyelin level abnormal increase of the disease caused by the use of the medicament. The invention of the general formula (I) compound of formula, its pharmaceutically acceptable salts or stereoisomers, can selectively inhibit sphingomyelin synthase, internal and external pharmacodynamic effects are significant, the safety is high.